Company / Operating Cash Flow
Beta Bionics, Inc. Operating Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$50.9M
FY2025
5-year range
-$50.9M / -$32.4M
FY2023-FY2025
Trend
-5.5%
vs FY2024
Sector context
#151 of 164
Health Care
What the data says
Among 164 Health Care companies, Beta Bionics, Inc. is in the bottom 8% for operating cash flow. Declined from -$32M to -$51M over the past 2 years.
Based on SEC 10-K filings.
-$51M in FY2025.
Declined from -$32M to -$51M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 164This company -$50.9M Sector average $1.0B
▼
-104.9% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 5.5% year-over-year.
- Ranks #151 out of 164 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$50.9M | -5.5% |
| FY2024 | -$48.3M | -48.8% |
| FY2023 | -$32.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026